<option id="y28yn"></option>
    <bdo id="y28yn"><optgroup id="y28yn"></optgroup></bdo>

    <track id="y28yn"></track>

      <tbody id="y28yn"><div id="y28yn"></div></tbody>
    1. <tbody id="y28yn"><div id="y28yn"><td id="y28yn"></td></div></tbody>
      <track id="y28yn"><div id="y28yn"></div></track>
      寧波亞川生物醫藥有限公司
      行業動態
      [GMP] FDA對印度Srikem發布警告信: 數據完整性與實驗室管理問題
      Your Preferred Partner to Compliance
       
       
      November 8, 2016
       
      Mr. Srinivasan Subramaniam
      Managing Director
      Srikem Laboratories Pvt. Ltd.
      Plot No. 17/24, MIDC Taloja
      Navi Mumbai, MH 410208
      India
       
      Dear Mr. Subramaniam:
       
      The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Srikem Laboratories Pvt. Ltd., Plot No. 17/24, MIDC Taloja, Navi Mumbai, from December 14 to 18, 2015.
      FDA在2015年12月14-18日檢查了你們在孟買的生產場所。
       
      This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).
      本警告信總結了你們原料藥生產CGMP嚴重違規情況。
       
      Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).
      由于你們生產、加工、包裝和保存的方法、設施和控制不符合CGMP要求,你們的藥品根據FDCA的定義被認為是摻假藥品。 
       
      We reviewed your January 12, 2016, response in detail and acknowledge receipt of your subsequent correspondence.
      我們詳細審核了你們于2016年1月12日及隨后發來的回復。
       
      During our inspection, our investigators observed specific deviations, including, but not limited to, the following.
      在我們檢查期間,我們的調查人員發現的違規情況包括但不僅限于以下:
       
      1. Failure to have laboratory control records that include complete data derived from all laboratory tests conducted to ensure compliance with established specifications and standards.
      化驗室檢驗記錄沒有來自所有化驗室檢驗中產生的完整數據,這些檢測是為了確保藥品符合既定質量標準而實施的。
      The audit trail for High Performance Liquid Chromatography (HPLC) instrument QCIEQPI40 showed multiple integrations conducted on the 18-month stability tests for unknown impurity content for (b)(4), USP lots (b)(4), without appropriate documentation, justification, and investigation.
      HPLC儀器QCIEQP140儀器的審計追蹤顯示某USP批號某產品18個月穩定性檢測有未知雜質含量多個積分,但沒有適當的文件記錄、論證和調查。
       
      Your quality assurance manager agreed that these integrations were inappropriate. When our investigator asked you to reprocess the chromatograms using appropriate integration parameters, the results were out-of-specification for unknown impurity content. Your quality unit must review all pertinent analytical data when making batch release decisions in order to determine batch quality.
      你們質量保證部經理認可這些積分是不恰當的。當我們的調查人員要求你們使用適當的積分參數對這些色譜數據進行重新處理時,處理結果顯示未知雜質含量超標。你們的質量部門在做出批放行決策時必須審核所有相關的分析數據,以確定批產品質量。
       
      In your response, you provided passing 24-month stability results for (b)(4) lots (b)(4), and committed to use the auto integration function. Your response is inadequate because it does not address the failing 18-month stability results for these lots and does not demonstrate how you will ensure that you retain complete and accurate records of all tests.
      在你們的回復中,你們提供了該批號24個月的穩定性結果,承諾要使用自動積分功能。你們的回復是不充分的,因為回復并沒有對失敗的18個月穩定性結果進行說明,也沒有證明你們要如何確保你們能夠保存所有檢測的準確完整記錄。
       
      2. Failure to follow and document laboratory controls at the time of performance.
      未能在實施檢驗時遵守和記錄化驗室檢驗情況。
       
      Our investigator observed inconsistently-dated laboratory records. For example, your executed protocol records show that a 24-month time-point stability testing sample of (b)(4), USP batch (b)(4), entered the laboratory on February 14, 2015. Our investigator requested the HPLC data. You provided our investigator HPLC chromatogram printouts showing that the sample was tested on February 12 and 13, 2015: one or two days before your protocol shows that the samples even entered the lab. You were unable to find any raw data corresponding to these tests. The use-log of the HPLC does not contain entries for these runs.
      我們的調查人員發現化驗室記錄日期不一致的情況。例如,你們實施的方案記錄顯示24個月穩定性測試樣品是在2015年2月14日進入化驗室的。我們的調查人員要求查看HPLC數據。你們給我們調查人員提供的HPLC圖譜打印件顯示樣品是在2015年2月12日和13日檢測的,在你們的方案顯示樣品甚至還沒進到化驗室的1-2天之前。你們沒有發現對應這些測試的原始數據。HPLC的使用日志也沒有這些樣品檢驗運行的記錄。
       
      In another example, a printed chromatogram from related substance analysis performed by gas chromatography for (b)(4), batch (b)(4), was dated August 26, 2014. The data saved to your computer system from this analysis was dated December 28, 2013: nearly eight months before the date on the printed chromatogram.
      在另一個例子中,GC對某批號所做的有關物質分析打印圖譜里,日期是2014年8月26日。在你們的電腦系統中存貯的此分析的日期為2013年12月28日:比打印圖譜早了接近8個月。
       
      In your response, you attributed data discrepancies to software malfunctions, power outages, and personnel shift changes. Your response is inadequate because you have not sufficiently explained how you are improving controls, notwithstanding these claimed sources of discrepancies, to ensure the reliability and accuracy of the data you rely on to evaluate the quality of your drugs.
      在你們的回復中,你們將數據不一致歸結于軟件故障,斷電和人員換班。你們的回復是不充分的,因為你們沒有充分地解釋你們要如何改善你們的控制,不管這些所聲明的不一致的原因是什么,都應確保你們賴以評估你們藥品質量的數據的準確性。
       Data Integrity Remediation  數據完整性彌補措施

      Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. We acknowledge that you are using a consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide the following.
      你們的質量體系不能充分確保數據的準確性和完整性,無法支持你們生產的藥品的安全性、有效性和質量。我們知道你們聘請了顧問來審計你們的操作,協助符合FDA要求。在回復此函時,提供以下資料:

      A.  A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include: 
      一份對數據記錄和報告不準確性程度的全面調查。你們的調查應包括:
      A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.
      詳細的調查方案和方法學;對評估所覆蓋的所有化驗室、生產操作和系統的總結,以及對你們意在排除的操作中所有部分的論證。
      Interviews of current and former employees to identify the nature, scope, and root cause of da
      ta inaccuracies. We recommend that these interviews be conducted by a qualified third party.
      與現有的和已離職的員工進行面談,找出數據不準確的表現、范圍、根本原因。我們建議這些面談由一個有資質的第三方來實施。
      An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.
      你們工廠數據完整性缺陷的程度的評估。識別出省略、修改、刪除、記錄銷毀、不同步記錄填寫和其它缺陷。描述你們工廠操作中發現數據完整性問題的所有部分。數據完整性問題的根本原因的描述,包括認定當前行動計劃的范圍和深度與調查和風險評估發現相稱的證據。說明是否對數據完整性問題承擔責任的個人仍有能力對你公司對CGMP相關或藥物應用數據產生影響。
      Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.
      臨時描述,描述你們已采取的行動,或即將采取用以保護患者確保你們藥品質量的努力,例如通知你們的客戶、召回產品、實施額外測試、向穩定性試驗計劃中增加批次以確保穩定性、藥品申報行動以及加強投訴監測。Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data.
      長期措施,其中描述所有對用以確保你們公司數據完整性的程序、流程、方法、控制、系統、管理監管和人力資源(例如培訓、員工提高)的彌補和提升。
      A status report for any of the above activities already underway or completed.
      對上述活動已開展或已經完成的狀態報告。
       
      Conclusion
       
      Deviations cited in this letter are not intended as an all-inclusive list. You are responsible for investigating these deviations, for determining the causes, for preventing their recurrence, and for preventing other deviations in all your facilities.
       
      If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b) and allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.
       
      FDA placed your firm on Import Alert 66-40 on July 6, 2016.
       
      Until you correct all deviations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer.
       
      Failure to correct these deviations may also result in FDA continuing to refuse admission of articles manufactured at Srikem Laboratories Pvt. Ltd. Plot No. 17/24, MIDC Taloja, Navi Mumbai, MH 410208, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Under the same authority, articles may be subject to refusal of admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
       
      After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your deviations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.
       
      Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov or mail your reply to:
            Carlos Gonzalez, Compliance Officer
            U.S. Food and Drug Administration
            White Oak, Building 51 Room 4359
            10903 New Hampshire Avenue
            Silver Spring, MD 20993
            USA
       
      Please identify your response with FEI 3005048741.
       
      Sincerely,
       
      Francis Godwin
      Acting Director
      Office of Manufacturing Quality
      Office of Compliance
      Center for Drug Evaluation and Research
      返回主目錄
       
      點擊這里給我發消息
      在線客服01
      點擊這里給我發消息
      在線客服02
      點擊這里給我發消息
      在線客服03
       
       
       
       
      国产精品美女www爽爽爽视频&欲色精品一区二区三区99&亚洲日本香蕉观看观视频&av无毒无码亚洲国产

        <option id="y28yn"></option>
        <bdo id="y28yn"><optgroup id="y28yn"></optgroup></bdo>

        <track id="y28yn"></track>

          <tbody id="y28yn"><div id="y28yn"></div></tbody>
        1. <tbody id="y28yn"><div id="y28yn"><td id="y28yn"></td></div></tbody>
          <track id="y28yn"><div id="y28yn"></div></track>